STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION 
For procedures finalised after 1 May 2002 please refer to module 8B. 
Extension (change of source of active substance) 
The company Hoechst Marion Roussel GmbH, Germany, submitted on 1 October 1997 to the EMEA 
an  application  to  obtain  a  Marketing  Authorisation  in  accordance  with  Annex  II  of  Commission 
Regulation (EC) No  542/95 of  10 March  1995  (part VI)  for the  medicinal  product Insuman (human 
insulin). 
- 
- 
- 
- 
- 
- 
- 
- 
The procedure for Insuman started on 24 October 1997.  
The  Rapporteur's  first  assessment  report  was  circulated  to  all  CPMP  Members  on  9  January 
1998.  
During the CPMP plenary  meeting on 24 February 1998, the CPMP adopted the consolidated 
list  of  questions  for  Insuman  to  be  sent  to  the  company.  The  CPMP  consolidated  list  of 
questions was sent to the company on 25 February 1998. 
The company submitted the responses to the consolidated list of questions on 8 April 1998.  
The Rapporteur circulated the joint response assessment report on the company’s responses to 
the list of questions to all CPMP Members on 25 May 1998.  
The CPMP, during its meeting on 23 June 1998, discussed the recommendations presented by 
the Rapporteur, considering the responses provided by the company satisfactory. 
The  CPMP  during  its  meeting  of  23-25  June  1998  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation to Insuman on 24 June 1998. 
The Commission Decision for this extension was issued on 11 November 1998. 
Subsequent extensions 
Additional route of administration for Insuman Rapid: intravenous use 
On  20  January  2000,  the  CPMP  issued  a  positive  opinion  for  Insuman  Rapid,  intravenous  use. 
Insuman Rapid administered intravenously is suitable for the treatment of hyperglycaemic coma and 
ketoacidosis,  as  well  as  for  achieving  pre-,  intra-  and  post-operative  stabilisation  in  patients  with 
diabetes mellitus. In addition the Part II of the dossier was updated to take into account the change in 
Insuman Rapid from the previous source (insulin HGT) to the new source of active ingredient (insulin 
HR1799).  Minor  changes  to  the  manufacturing  process  were  also  introduced.  The  Commission 
Decision for this extension was issued on 01 August 2000. 
Variations 
All  variations  and  notifications  agreed  upon  after  granting  the  Marketing  Authorisation  are 
summarised in the table below. 
1/2 
EMEA 2005 
 
 
 
 
 
 
 
 
 
 
Scope 
Type of 
modification1 
Submission 
date 
Notification/ 
Opinion Date 
CPMP 
opinion 
Additional pack size: 4 cartridges 
for Insuman (Rapid, Basal, Comb 
15, Comb 25, Comb 50)  
Additional pack size: 10 
cartridges for Insuman (Rapid, 
Basal, Comb 15, Comb 25, Comb 
50) 
Additional presentations: Insuman 
in a pre-filled disposable injection 
pen: Insuman OptiSet (Rapid, 
Basal, Comb 15, Comb 25, Com 
50) 
Update of Part II of the dossier to 
take into account the change from 
the previous source (insulin HGT) 
to the new source of active 
ingredient (insulin HR1799) and 
additional minor changes to the 
manufacturing process 
Change to the specifications of 
the active substance 
Change in test procedure of active 
substance 
Change(s) to the manufacturing 
process for the active substance   
Update of Summary of Product 
Characteristics and Package 
Leaflet 
Change in the name and/or 
address of the marketing 
authorisation holder (from 
Hoechst Marion Roussel 
Deutschland GmbH to Aventis 
Pharma Deutschland GmbH) 
Change following modification(s) 
of the manufacturing 
authorisation(s) 
Change in the name of a 
manufacturer of the active 
substance 
Update of or change(s) to the 
pharmaceutical documentation 
Change in specification of  
medicinal product 
Renewal of the Marketing 
Authorisation 
Change(s) to the test method(s) 
and/or specifications for the 
finished product 
II 
II 
II 
II 
II 
I/II 
II 
II 
I 
II 
I 
R 
II 
Change 
in 
Comm. 
Decision 
Annex I, 
III 
Date of 
Comm. 
Decision 
18.02.99 
1 
27.11.98 
16.12.99 
Change 
accepted 
27.11.98 
16.12.99 
Change 
accepted 
Annex I, 
III 
18.02.99 
2 
12.07.99 
18.11.99 
Change 
accepted 
Annex I, 
III 
20.03.00 
4 
10.08.99 
20.01.00 
Change 
accepted 
- 
22.02.00 
5 
13.10.99 
13.04.00 
05.07.00 
19.10.00 
05.08.00 
19.10.00 
16.08.00 
14.12.00 
14.08.00 
21.12.00 
Change 
accepted 
Change 
accepted 
Change 
accepted 
Change 
accepted 
Change 
accepted 
- 
- 
- 
I, IIIA, 
IIIB 
I, II, 
IIIA, 
IIIB 
28.04.00 
15.11.00 
15.11.00 
14.06.01 
6 
7 
8 
9 
- 
10 
01.12.00 
26.04.01 
08.10.01 
12.12.01 
08.10.01 
13.12.01 
26.11.01 
25.04.02 
Change 
accepted 
Change 
accepted 
Accepted 
Change 
accepted 
- 
- 
I, II, 
IIIA, 
IIIB 
- 
04.05.01 
11 
- 
12 
22.03.02 
13 
30.04.02 
14 
1 T: Transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 of  7 November 1996. 
I, II, I/II: In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: I refers to a minor variation (type I 
variation); II refers to a major variation (type II variation); I / II refers to a minor variation following the procedure set out in Article 6, 7 and 
8 of the Regulation. 
2/2 
EMEA 2005 
 
 
 
 
 
 
 
 
                                                            
